Preview Mode Links will not work in preview mode

Feb 23, 2024

Featuring perspectives from Dr Ahmed Omar Kaseb and Prof Arndt Vogel, including the following topics:

  • Introduction: EMERALD-1 — Immune Checkpoint Inhibitor-Based Therapy for Localized HCC Eligible for Embolization (0:00)
  • Optimal Utilization of Immune Checkpoint Inhibitors as First-Line Therapy for Advanced HCC – Dr...


Feb 20, 2024

Featuring perspectives from Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Dr Elisabeth I Heath and Dr A Oliver Sartor, moderated by Dr Alan H Bryce, including the following topics:

  • Introduction (0:00)
  • Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Aggarwal (1:51)
  • Evidence-Based Selection of Treatment...


Feb 16, 2024

Featuring perspectives from Dr Bradley J Monk, including the following topics:

  • Introduction (0:00)
  • Case: A woman (gBRCA1) in her late 40s, 5 months after surgery and adjuvant paclitaxel/carboplatin for Stage II ovarian cancer, now with a single umbilical metastasis — Kellie E Schneider, MD (9:47)
  • Case: A woman...


Feb 15, 2024

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Andrea Cercek, Dr Cathy Eng and Dr John Strickler, moderated by Dr Christopher Lieu, including the following topics:

  • Introduction (0:00)
  • Optimizing Biomarker Assessment and Treatment for Patients with Metastatic Colorectal Cancer (mCRC) — Dr Eng (2:48)
  • Emerging...


Feb 9, 2024

Featuring perspectives from Dr Matthew Milowsky, Dr Peter H O’Donnell, Dr Jonathan E Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Evan Y Yu, including the following topics:

  • Introduction (0:00)
  • Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr...